Quantum Genomics S.A.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a QNNTF research report →
Companywww.quantum-genomics.com
Quantum Genomics Société Anonyme, a biopharmaceutical company, develops drugs to treat cardiovascular diseases. It develops drugs based on brain aminopeptidase A inhibition (BAPAI) platform primarily to treat high blood pressure and heart failure. The company develops firibastat, a monotherapy drug that is in pivotal Phase III study for the treatment of hypertension, as well as in clinical trial for the treatment of heart failure.
- CEO
- Mathieu Bigois
- IPO
- 2021
- Employees
- 3
- HQ
- Paris, FR
Price Chart
Valuation
- Market Cap
- $6.96M
- P/E
- -0.57
- P/S
- 499945.80
- P/B
- -2.05
- EV/EBITDA
- -4.99
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -11453070.00%
- Op Margin
- -14728350.00%
- Net Margin
- -88926030.00%
- ROE
- 880.77%
- ROIC
- -153.05%
Growth & Income
- Revenue
- $10 · -99.95%
- Net Income
- $-8,892,603 · -180.44%
- EPS
- $-0.13 · -42.86%
- Op Income
- $-1,472,835
- FCF YoY
- 0.00%
Performance & Tape
- 52W High
- $0.10
- 52W Low
- $0.10
- 50D MA
- $0.10
- 200D MA
- $0.10
- Beta
- 0.16
- Avg Volume
- 1.91K
Get TickerSpark's AI analysis on QNNTF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our QNNTF Coverage
We haven't published any research on QNNTF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate QNNTF Report →